Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease |
| |
Authors: | Francesco Di Mario MD Giovanni Aragona MD Gioacchino Leandro MD Giuseppe Comparato MD Libera Fanigliulo MD Lucas G Cavallaro MD Giulia M Cavestro MD Veronica Iori MD Marta Maino MD AlÌ M Moussa MD Alessandro Gnocchi MD Giancarlo Mazzocchi MD Angelo Franzé MD |
| |
Institution: | (1) Chair of Gastroenterology, University of Parma, Parma, Italy;(2) Gastroenterological Hospital S. De Bellis, IRCCS, Castellana Grotte, Bari, Italy;(3) Gastroenterology and Endoscopy Unit, Az. Ospedaliera, Parma, Italy;(4) U.O. Chirurgia Borgovalditaro, AUSL, Parma, Italy;(5) Università degli Studi di Parma, Dipartimento di Scienze Cliniche, sezione di Gastroenterologia, Via Gramsci 14, Parma, 43100, Italy |
| |
Abstract: | We aimed to improve symptoms by means of mesalazine in symptomatic colonic diverticular disease patients. One hundred seventy outpatients (98 M, 72 F; age, 67.1 years; range, 39–84 years) were assigned to four different schedules: rifaximin, 200 mg bid (Group R1: 39 pts), rifaximin, 400 mg bid (Group R2: 43 pts), mesalazine, 400 mg bid (Group M1: 40 pts), and mesalazine, 800 mg bid (Group M2: 48 pts), for 10 days per month. At baseline and after 3 months we recorded 11 clinical variables (upper/lower abdominal pain/discomfort, bloating, tenesmus, diarrhea, abdominal tenderness, fever, general illness, nausea, emesis, dysuria), scored from 0 = no symptoms to 3 = severe. The global symptomatic score was the sum of all symptom scores. After 3 months in all schedules but Group R1, 3 of the 11 symptoms improved (P < 0.03); the global score decreased in all groups but Group R1 (P < 0.0001). Mesalazine-treated patients had the lowest global score at 3 months (P < 0.001). Mesalazine is as effective as rifaximin (higher dosage schedule) for diminishing some symptoms, but it appears to be better than rifaximin for improving the global score in those patients.This work was carried out under the auspices of the Roberto Farini Foundation for Gastroenterological Research. |
| |
Keywords: | mesalazine diverticular disease diverticula rifaximin |
本文献已被 PubMed SpringerLink 等数据库收录! |
|